navex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL) today announced that United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,446,275 to Anavex, with claims to treatment methods using its leading drug candidate, ANAVEX2-73 (blarcamesine) and its analogs, for ameliorating biochemical and functional abnormalities associated with methyl-CpG binding protein 2 defects (MeCP2 defects). Such defects encompass a range of neurodevelopmental and neurological disorders, including but not limited to, Rett syndrome, Angelman syndrome, Williams syndrome, cerebral palsy, autism spectrum disorder, and multiple sclerosis. Anavex's newest patent is the latest in a series of patents recently granted to Anavex and is expected to remain in force at least until 2037, not including any patent term extensions. Recent US patent grants to Anavex also include U.S. Patent No. 10,426,754 granted to Anavex in October 2019, U.S. Patent No. 10,507,196 granted to Anavex in December 2019, and U.S. Patent No. 10,888,543 granted to Anavex in January 2021. The new '275 patent adds to the comprehensive patent portfolio supporting ANAVEX2-73 (blarcamesine), and its analogs, such as ANAVEX1-41 and ANAVEX19-144, which are all orally available sigma-1 receptor (SIGMAR1) agonists. The '275 patent covers the therapeutic use of these compounds, including ANAVEX2-73 (blarcamesine), in oral, transdermal, and parenteral compositions to treat abnormalities associated with methyl-CpG binding protein 2 defects (MeCP2 defects).